Page last updated: 2024-09-24

aucubin

Cross-References

ID SourceID
PubMed CID91458
CHEMBL ID514882
CHEBI ID69796
SCHEMBL ID381032
MeSH IDM0049296

Synonyms (54)

Synonym
ACON1_002452
nsc-407293
479-98-1
aucubin
C09771
(2s,3r,4s,5s,6r)-2-[[(1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl]oxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
(2s,3r,4s,5s,6r)-2-((1s,4ar,5r,7as)-5-hydroxy-7-hydroxymethyl-1,4a,5,7a-tetrahydro-cyclopenta[c]pyran-1-yloxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
MEGXP0_001729
einecs 207-540-8
nsc 407293
1,4a,5,7a-tetrahydro-5-hydroxy-7-hydroxymethylcyclopenta(c)pyran-1-yl-beta-d-glucopyranoside
(1s-(1alpha,4aalpha,5alpha,7aalpha))-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-beta-d-glucopyranoside
NCGC00169833-01
LMPR0102070006
rhinanthin
smr001397339
MLS002473252
chebi:69796 ,
CHEMBL514882
(2s,3r,4s,5s,6r)-2-[[(1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
HMS3098B08
b-d-glucopyranoside, (1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl
A827419
unii-2g52gs8uml
2g52gs8uml ,
AKOS015896774
S5459
(1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-.beta.-d-glucopyranoside
aucuboside
aucubin [mi]
HY-N0664
CS-5367
SCHEMBL381032
AC-33938
Q-100516
RJWJHRPNHPHBRN-FKVJWERZSA-N
.beta.-d-glucopyranoside, (1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl
(2s,3r,4s,5s,6r)-2-(((1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
mfcd00136026
rhimantin
aucubin, primary pharmaceutical reference standard
aucubin, analytical standard
(2s,3r,4s,5s,6r)-2-{[(1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1h,4ah,5h,7ah-cyclopenta[c]pyran-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
AS-74899
NCGC00169833-02
(2s,3r,4s,5s,6r)-2-((1s,4ar,5s,7as)-5-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
Q418014
aucubuside
DTXSID60963965
CCG-267985
(1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl beta-d-glucopyranoside
aucubin (constituent of chaste tree)
(1s,4ar,5s,7as)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-beta-d-glucopyranoside
aucubine

Research Excerpts

Overview

ExcerptReference
"Aucubin is an iridoid glycoside that is widely distributed in green plants and exhibits various biological activities such as antioxidant, anti-inflammatory, and protecting the liver. "( Leng, X; Li, X; Tan, H; Xu, X; Xu, Z; Yang, H, 2022)
"Aucubin is an iridoid glycoside widely spread in the families "( Irawan, MA; Jayani, NIE; Kartini, K; Setiawan, F, 2023)
"Aucubin is an iridoid glycoside that is widely prevalent in traditional medicinal herbs, such as Eucommia ulmoides Oliv., Aucuba japonica Thunb. "( Guo, F; Ouyang, D; Zeng, X, 2020)
"Aucubin (AU) is an iridoid glycoside and that is one of the active constituents of Eucommia ulmoides, has many pharmacological effects such as anti-inflammation, anti-liver fibrosis, and anti-atherosclerosis."( Cao, YJ; Hao, JC; He, XZ; Jing, HL; Li, Y; Li, YC; Shang, B; Tian, QQ; Wang, LJ; Wang, ZL; Yang, KL; Zhao, C, 2021)
"Aucubin (AU) is an iridoid glycoside that has been shown to display estrogenic properties and has various pharmacological effects. "( Chen, L; Coffie, JW; Fang, Z; Gao, X; Geng, X; Li, C; Qiu, L; Song, M; Wang, H; Yang, Y; You, X; Zhang, L, 2017)
"Aucubin is a natural constituent with a monoterpene cyclic ring system."( Duan, JX; Guan, CX; Guan, XX; Li, P; Liu, T; Liu, YP; Mei, WX; Ouyang, DS; Sun, GY; Wan, L; Zhong, WJ; Zhou, Y, 2017)
"Aucubin (ACB) is an iridoid glycoside with various biological activities. "( Han, M; Kim Kwon, Y; Song, M, 2018)
"Aucubin (AUC) is a major bioactive ingredient in Eucommia ulmoides, Plantain asiatica, and Aucuba japonica, and has been shown to exert anti-inflammatory, antioxidative, and neuroprotective effects. "( Chen, X; Cui, C; Jia, XB; Shen, YQ; Sun, MF; Xu, YD; Xu, ZH; Yang, XS; Zhang, PH; Zhou, ZL; Zhu, YL, 2018)
"Aucubin (AU) is an iridoid glycoside derived from Eucommia ulmoides that possesses anti-inflammatory and neuroprotective effects."( Chen, L; Chen, S; Hu, K; Huang, Q; Huang, X; Li, C; Ouyang, DS; Wang, X; Zeng, G; Zeng, X; Zhou, L; Zong, W, 2019)
"Aucubin is an active component extracted from Eucommia ulmoides, which has liver-protection effects."( Feng, H; Hu, K; Huang, WH; Li, XH; Lv, PY; Ouyang, DS; Qin, YH; Tian, YY; Wang, YQ; Zhou, HH, 2017)

Effects

ExcerptReference
"Aucubin (AU) has been proven to exhibit highly effective anti-inflammatory activity, but its ability to protect against endometritis in dairy cows remains unclear."( Cao, R; Feng, Y; Fu, K; Gao, F; Li, H; Tian, W, 2021)

Actions

ExcerptReference
"Aucubin can enhance the anti-catabolic and anti-inflammatory effects of HA on OA chondrocytes."( Chen, YR; Huang, TL; Liao, JY; Tang, Y; Yang, KC; Yang, SH, 2019)

Treatment

ExcerptReference
"Aucubin treatment significantly reverses IL-1β-induced cytotoxicity and attenuated the IL-1β-induced chondrocyte apoptosis."( Chen, PS; Jiang, Y; Wang, BW; Wang, SN; Yao, ZL; Yu, B, 2019)
"Treatment with aucubin by both routes of administration ameliorated histopathological changes and reduced elevated serum markers of kidney injury."( Batičić, L; Broznić, D; Domitrović, R; Marinić, J; Potočnjak, I; Šimić, L, 2020)
"Pretreatment with aucubin significantly inhibited the production of MMP-1 by 57% when compared to the UVB-irradiated cells."( Cho, HY; Ho, JN; Hong, BS; Jun, WJ; Kim, HK; Lee, YH; Park, JS; Shin, DH, 2005)
"Treatment of aucubin (1) with tert-butyldimethylsilyl chloride under alkaline conditions permitted regioselective silylation of either the primary hydroxyl groups at C-9 and C-6' or both primary hydroxyl groups and the secondary allylic hydroxyl group at C-6. "( Deguin, B; Koch, M; Laschiazza, R; Lecsö-Bornet, M; Rakotondramasy, VC; Tillequin, F, 2007)

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency0.06310.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency0.18360.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID334194Inhibition of classical complement pathway activation at 4 uM assessed as complement modulation test2003Journal of natural products, Jan, Volume: 66, Issue:1
Complement-inhibiting iridoids from Morinda morindoides.
AID1301498Cytotoxicity against human HT-29 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID1251038Inhibition of COX1 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID1301499Cytotoxicity against human Bel7402 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID1301497Cytotoxicity against human A549 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1251039Inhibition of COX2 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID642415Estrogenic activity at ERalpha in human MVLN cells at 20 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID1251037Inhibition of COX1 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID467894Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml measured after 72 hrs by luciferase reporter gene assay2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID1251040Inhibition of COX2 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID1301501Cytotoxicity against human A2780 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID642414Estrogenic activity at ERalpha in human MVLN cells at 100 ug/mL after 24 hrs by luciferase reporter gene assay relative to E22012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of estrogen receptor α modulators from natural compounds in Si-Wu-Tang series decoctions using estrogen-responsive MCF-7 breast cancer cells.
AID1301500Cytotoxicity against human BGC823 cells by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID1251041Inhibition of COX2 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID334195Inhibition of classical complement pathway activation at 4 uM in presence of beta glucosidase by complement modulation test2003Journal of natural products, Jan, Volume: 66, Issue:1
Complement-inhibiting iridoids from Morinda morindoides.
AID1251036Inhibition of COX1 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (155)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (5.81)18.7374
1990's6 (3.87)18.2507
2000's36 (23.23)29.6817
2010's68 (43.87)24.3611
2020's36 (23.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other156 (97.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (2)

ArticleYear
Aucubin protects mouse cochlear hair cells from cisplatin-induced ototoxicity via activation of the PI3K/AKT/STAT3 pathway.
Biochemical pharmacology, Volume: 209
2023
Eucommia ulmoides cortex, geniposide and aucubin regulate lipotoxicity through the inhibition of lysosomal BAX.
PloS one, Volume: 9, Issue: 2
2014
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (6)

ArticleYear
Determination of aucubin by supramolecular solvent-based dispersive liquid-liquid microextraction and UPLC-MS/MS: Application to a pharmacokinetic study in rats with type 1 diabetes.
Journal of pharmaceutical and biomedical analysis, Jul-15, Volume: 186
2020
Pharmacokinetics and tissue distribution of five active ingredients of Eucommiae cortex in normal and ovariectomized mice by UHPLC-MS/MS.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 46, Issue: 9
2016
Pharmacokinetics and tissue distribution of Aucubin, Ajugol and Catalpol in rats using a validated simultaneous LC-ESI-MS/MS assay.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Oct-01, Volume: 1002
2015
Development and validation of high liquid performance chromatography-tandem mass spectrometry method for simultaneous determination of geniposidic acid and aucubin in rat plasma for pharmacokinetic study after oral administration of Du-zhong tea extract.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Jul-15, Volume: 963
2014
A rapid and sensitive determination of aucubin in rat plasma by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application.
Biomedical chromatography : BMC, Volume: 26, Issue: 9
2012
Pharmacokinetic study of an iridoid glucoside: aucubin.
Pharmaceutical research, Volume: 8, Issue: 8
1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (4)

ArticleYear
A review of the pharmacology and toxicology of aucubin.
Fitoterapia, Volume: 140
2020
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5
2019
Pharmacokinetics and tissue distribution of five active ingredients of Eucommiae cortex in normal and ovariectomized mice by UHPLC-MS/MS.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 46, Issue: 9
2016
Pharmacokinetic study of an iridoid glucoside: aucubin.
Pharmaceutical research, Volume: 8, Issue: 8
1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (2)

ArticleYear
[Study on optimizing the analysis condition for active compound in Eucommia olive].
Guang pu xue yu guang pu fen xi = Guang pu, Volume: 24, Issue: 12
2004
Mechanism of covalent adduct formation of aucubin to proteins.
Toxicology letters, Apr-03, Volume: 114, Issue: 1-3
2000
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Natural Sources (1)

ArticleYear
Iridoid glucosides in the genus Veronica (Plantaginaceae) from New Zealand.
Phytochemistry, Volume: 140
2017
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]